Human parainfluenza virus type 2 V protein inhibits induction of tetherin
Sign Up to like & getrecommendations! Published in 2017 at "Medical Microbiology and Immunology"
DOI: 10.1007/s00430-017-0508-z
Abstract: Tetherin is an anti-viral factor that restricts viral budding through tethering virions to the cell surface. The human parainfluenza virus type 2 (hPIV-2) V protein decreases cell surface tetherin in HeLa cells, which constitutively express… read more here.
Keywords: protein; human parainfluenza; tetherin; infection ... See more keywords
Tetherin antagonism by V proteins is a common trait among the genus Rubulavirus
Sign Up to like & getrecommendations! Published in 2017 at "Medical Microbiology and Immunology"
DOI: 10.1007/s00430-017-0509-y
Abstract: Tetherin (BST-2/CD317/HM1.24) is an anti-viral factor that restricts the budding of several enveloped viruses. Most of these viruses have evolved to encode tetherin antagonists. Our previous study demonstrated that the growth of human parainfluenza virus… read more here.
Keywords: genus rubulavirus; proteins common; tetherin; tetherin antagonism ... See more keywords
OP0235 A novel B cell specific IFN-I biomarker is associated with plasmablast numbers following B cell depletion therapy in SLE
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.6423
Abstract: Background SLE is a Type I interferon (IFN-I) mediated disease with autoreactive B cells. Plasmablasts, the immediate progeny of B cells, are expanded in SLE and correlate with disease activity. We showed that their rate… read more here.
Keywords: rituximab; cell depletion; tetherin; ifn ... See more keywords
FRI0680 Tetherin, a novel type i interferon biomarker on blood leucocytes can capture interferon status and correlates with ustekinumab (STELARA) therapy response in psoriatic disease.
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.7267
Abstract: Background: Recently Ustekinumab, an IL12/23 p40 monoclonal antibody that is licensed for Psoriatic Arthritis and Psoriasis, showed promising results in phase II trials in SLE- a prototype IFN mediated disease. We previously confirmed a novel… read more here.
Keywords: ifn; tetherin; interferon; disease ... See more keywords